27EC Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University

Scott A. Waldman, MD, PhD

Contact Dr. Waldman

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-6086
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. A novel CDX2 isoform regulates alternative splicing
  2. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  3. Managing the innovation supply chain to maximize personalized medicine
  4. Antiobesity pharmacotherapy: New drugs and emerging targets
  5. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
  6. Policies to aid the adoption of personalized medicine
  7. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  8. Molecular insights provide the critical path to disease mitigation
  9. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer
  10. Erratum: Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter randomized trial with lineage-specified biologics (Journal of the American College of Cardiology (2013) 61 (2329-2338))
  11. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update a scientific statement from the american heart association
  12. Reply: The C-CURE randomized clinical trial (Cardiopoietic stem Cell therapy in heart failURE)
  13. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer
  14. Advances in cancer immunotherapy
  15. Colorectal cancer immunotherapy
  16. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis
  17. Evidence-based guidelines for precision risk stratification- based screening (PRSBS) for colorectal cancer: Lessons learned from the us armed forces: Consensus and future directions
  18. Molecular staging of node negative patients with colorectal cancer
  19. Systems approaches evolve clinical pharmacology
  20. Cardiopoietic stem cell therapy in heart failure: The C-CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics